Published in J Clin Invest on December 01, 1968
Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther (2008) 11.67
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest (1969) 2.47
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J (1990) 1.14
Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest (1970) 1.11
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Br Med J (1977) 1.06
Human FAD-dependent NAD(P)H diaphorase. Biochem J (1980) 1.05
A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. Br J Clin Pharmacol (1980) 1.01
Missing heritability of common diseases and treatments outside the protein-coding exome. Hum Genet (2014) 1.00
Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med (2010) 0.97
Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation. J Clin Invest (1977) 0.94
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. J Clin Invest (1983) 0.93
Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity. Expert Opin Drug Metab Toxicol (2008) 0.92
Enzyme induction and beta-adrenergic receptor blocking drugs. Br J Clin Pharmacol (1984) 0.86
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Pharmacogenomics in early-phase clinical development. Pharmacogenomics (2013) 0.83
Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery. Br J Clin Pharmacol (1980) 0.82
Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment. Environ Health Perspect (1977) 0.75
Metabolism of drugs. Br Med J (1970) 0.75
Oral anticoagulant therapy. Can Med Assoc J (1971) 0.75
The hydroxylation of drugs- a pharmacogenetic problem? Proc R Soc Med (1970) 0.75
Pharmacological implications of microsomal enzyme induction. Pharmacol Rev (1967) 13.35
The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 3.60
The fate of antipyrine in man. J Pharmacol Exp Ther (1950) 3.05
Genetic control of drug levels in man: antipyrine. Science (1968) 3.03
Genetic control of drug levels in man: phenylbutazone. Science (1968) 2.72
DIPHENYLHYDANTOIN METABOLISM, BLOOD LEVELS, AND TOXICITY. Arch Neurol (1964) 1.81
DRUG INTERACTIONS IN MAN. I. LOWERING EFFECT OF PHENOBARBITAL ON PLASMA LEVELS OF BISHYDROXYCOUMARIN (DICUMAROL) AND DIPHENYLHYDANTOIN (DILANTIN). Clin Pharmacol Ther (1965) 1.55
PHARMACOGENETICS. Prog Med Genet (1964) 1.33
The physiological disposition of dicumarol in man. J Pharmacol Exp Ther (1950) 1.17
Dose-dependence of drug plasma level decline in dogs. J Pharmacol Exp Ther (1967) 1.05
Stimulatory effect of nicotine on the metabolism of meprobamate. Toxicol Appl Pharmacol (1966) 1.02
The effect of caffeine on drug metabolism. Life Sci (1968) 1.01
MULTIFACTORIAL INHERITANCE AND HUMAN DISEASE. Prog Med Genet (1964) 0.97
Hemorrhagic state due to surreptitious ingestion of bishydroxycoumarin. A detailed case study. N Engl J Med (1962) 0.89
Genetic control of drug levels in man: antipyrine. Science (1968) 3.03
Genetic control of drug levels in man: phenylbutazone. Science (1968) 2.72
The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther (1979) 2.54
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest (1969) 2.47
Reduced warfarin binding of albumin variants. Science (1977) 1.73
Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther (1975) 1.65
Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med (1975) 1.57
Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther (1974) 1.56
Genetic and environmental factors affecting drug response in man. Fed Proc (1972) 1.50
Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin Pharmacol Ther (1990) 1.49
Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med (1974) 1.47
Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites. Clin Pharmacol Ther (1982) 1.44
Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med (1970) 1.44
Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol (1975) 1.43
Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther (1971) 1.41
Therapeutic drug monitoring. Clin Pharmacol Ther (1988) 1.40
Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther (1977) 1.35
Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Cancer Res (1976) 1.34
Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther (1975) 1.32
Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine. Clin Pharmacokinet (1980) 1.19
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol (1997) 1.16
Antipyrine metabolism during the menstrual cycle. Clin Pharmacol Ther (1980) 1.15
Genetic control of isozyme patterns in human tissues. Prog Med Genet (1965) 1.13
Therapeutic lessons from pharmacogenetics. Ann Intern Med (1997) 1.13
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med (1977) 1.13
Lactate dehydrogenase isozymes: kinetic properties at high enzyme concentrations. Science (1970) 1.12
Inhibition of theophylline metabolism by long-term allopurinol administration. Clin Pharmacol Ther (1981) 1.12
Genetic variation as a guide to drug development. Science (1998) 1.12
Temporal variations of antipyrine half-life in man. Clin Pharmacol Ther (1977) 1.10
Lactate and pyruvate concentrations in exercised ischemic canine muscle: relationship of tissue substrate level to lactate dehydrogenase isozyme pattern. Proc Natl Acad Sci U S A (1966) 1.10
Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokinet (1983) 1.09
Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther (1975) 1.07
Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem (1976) 1.07
Temporal variations in acetaminophen and phenacetin half-life in man. Clin Pharmacol Ther (1975) 1.05
Radioimmunoassay of plasma nicotine in habituated and naive smokers. Clin Pharmacol Ther (1974) 1.04
Quinine-induced alterations in drug disposition. Clin Pharmacol Ther (1975) 1.03
Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. Clin Pharmacol Ther (1978) 1.01
Concentration-dependent effects of fatty acids on warfarin binding to albumin. Biochem Pharmacol (1977) 1.01
Induction of drug-metabolizing enzymes in liver microsomes of mice and rats by softwood bedding. Science (1967) 1.01
Polygenic factors controlling drug response. Med Clin North Am (1974) 1.00
Hepatic drug metabolism in ten strains of Norway rat before and after pretreatment with phenobarbital. Proc Soc Exp Biol Med (1969) 0.98
Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci U S A (1981) 0.98
The roles of synthesis and degradation in determining tissue concentrations of lactate dehydrogenase-5. Proc Natl Acad Sci U S A (1969) 0.98
Cyclic hyperalimentation: an optimal technique for preservation of visceral protein. J Surg Res (1976) 0.97
Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs. Pharmacology (1973) 0.97
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet (1971) 0.96
Effects of metabolites of primaquine and acetanilid on normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. J Pharmacol Exp Ther (1968) 0.96
Comparative study of methods for quantitation of lactate dehydrogenase isozymes. Anal Biochem (1970) 0.96
Factors altering the responsiveness of mice to hexobarbital. Pharmacology (1968) 0.95
Protection of lactate dehydrogenase isozymes from heat inactivation and enzymatic degradation. Ann N Y Acad Sci (1968) 0.95
Unaltered metabolism of antipyrine and tolbutamide in fasting man. Clin Pharmacol Ther (1975) 0.94
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. J Clin Invest (1983) 0.93
Evidence for post-transcriptional stabilization of ribosomal precursor ribonucleic acid by phenobarbital. Mol Pharmacol (1972) 0.93
The binding of sulfaphenazole to fetal, neonatal, and adult human plasma albumin. Clin Pharmacol Ther (1972) 0.93
Heterogeneity of N-and O-methyltransferases. Mol Pharmacol (1970) 0.92
Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. Clin Pharmacol Ther (1978) 0.92
Metabolism of nicotine. Drug Metab Rev (1991) 0.92
Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther (1993) 0.92
Inhibition of drug metabolism in man. Drug Metab Dispos (1974) 0.92
Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res (1977) 0.91
Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. Drug Metab Dispos (1989) 0.91
Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol (1978) 0.91
Recent progress in pharmacogenetics. Adv Pharmacol Chemother (1969) 0.90
The nurse practitioner: management of minor trauma. Accid Emerg Nurs (1996) 0.90
Lactate dehydrogenase Isozymes: substrate inhibition in various human tissues. Science (1965) 0.90
Lactate dehydrogenase isozyme patterns of human platelets and bovine lens fibers. Science (1965) 0.90
Genetic and environmental factors affecting hexobarbital metabolism in mice. Ann N Y Acad Sci (1968) 0.90
Characterization of cytochrome P-450-dependent aminopyrine N-demethylase in rat brain: comparison with hepatic aminopyrine N-demethylation. J Pharmacol Exp Ther (1979) 0.90
Twin studies in pharmacogenetics. Hum Genet Suppl (1978) 0.89
Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. Drug Metab Dispos (1988) 0.89
Effects of leuprolide in the treatment of central precocious puberty. J Pediatr (1989) 0.89
Advances in pharmacogenetics. Prog Med Genet (1973) 0.89
Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition. Clin Pharmacol Ther (1977) 0.88
Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease. Clin Pharmacol Ther (1976) 0.88
Impairment of drug metabolism by disulfiram in man. Clin Pharmacol Ther (1971) 0.87
Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites. Clin Pharmacol Ther (1984) 0.87
New directions in pharmacogenetics: Introduction. Fed Proc (1984) 0.87
Influence of different forms of tobacco intake on nicotine elimination in man. Pharmacology (1983) 0.87
Polymorphism of theophylline metabolism in man. J Clin Invest (1985) 0.86
Environmental and genetic factors affecting the response of laboratory animals to drugs. Fed Proc (1976) 0.86
Failure of hydrocortisone to alter acutely antipyrine disposition. Clin Pharmacol Ther (1978) 0.85
High levels of methylxanthines in chocolate do not alter theobromine disposition. Clin Pharmacol Ther (1985) 0.85
Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol (1981) 0.85
Heterogeneous response of hepatic mixed function oxidases to chronic phenobarbital administration. Biochem Pharmacol (1979) 0.84
Species differences in inducibility of phenylethanolamine-N-methyl transferase. Endocrinology (1968) 0.84
Anomalous results of studies on drug interaction in man. III. Disulfiram and antipyrine. Pharmacology (1975) 0.84
Receptor-independent sequestration of beta-adrenergic ligands by alveolar type II cells. Am J Physiol (1986) 0.83
Pharmacological and toxicological evaluation of orally administered pyridostigmine in dogs. Fundam Appl Toxicol (1990) 0.83
Metabolism of nicotine by hepatocytes. Biochem Pharmacol (1990) 0.83
Selection of subjects for investigation of host factors affecting drug response: a method to identify new pharmacogenetic conditions. Clin Pharmacol Ther (1984) 0.83
NIH budget grows, but not R01 success rates. Science (2001) 0.83
Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. I. Analysis, characterization and regulation of specific beta adrenergic receptors. J Pharmacol Exp Ther (1987) 0.83
Hepatic drug metabolism in rats: impairment in a dirty environment. Science (1973) 0.83
Reproducibility of individual rates of ethanol metabolism in fasting subjects. Clin Pharmacol Ther (1990) 0.83
On the significance of host factors that affect drug disposition. Clin Pharmacol Ther (1982) 0.83